よむ、つかう、まなぶ。
03資料1-1森野委員提出資料（高齢者に対するインフルエンザワクチンファクトシート） (40 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_64997.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会 予防接種基本方針部会 ワクチン評価に関する小委員会（第32回 10／22）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
Seasonal Influenza. Am J Med 2018; 131(8): 865-73.
61.
Lu Y, Chillarige Y, Izurieta HS, et al. Effect of Age on Relative Effectiveness of High-Dose
Versus Standard-Dose Influenza Vaccines Among US Medicare Beneficiaries Aged ≥65 Years. J Infect Dis
2019; 220(9): 1511-20.
62.
DiazGranados CA, Dunning AJ, Robertson CA, Talbot HK, Landolfi V, Greenberg DP. Effect of
Previous-Year Vaccination on the Efficacy, Immunogenicity, and Safety of High-Dose Inactivated
Influenza Vaccine in Older Adults. Clin Infect Dis 2016; 62(9): 1092-9.
63.
Christensen J, Johansen ND, Modin D, et al. Relative Effectiveness of High-Dose Versus
Standard-Dose Quadrivalent Influenza Vaccine in Older Adults With Cardiovascular Disease: A
Prespecified Analysis of the DANFLU-1 Randomized Clinical Trial. Circ Cardiovasc Qual Outcomes
2025; 18(2): e011496.
64.
Chaves SS, Naeger S, Lounaci K, et al. High-Dose Influenza Vaccine Is Associated With
Reduced Mortality Among Older Adults With Breakthrough Influenza Even When There Is Poor VaccineStrain Match. Clin Infect Dis 2023; 77(7): 1032-42.
65.
DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-dose
influenza vaccine in older adults. N Engl J Med 2014; 371(7): 635-45.
66.
独立行政法人医薬品医療機器総合機構. 審査報告書
高用量インフルエンザ HA ワクチン.
2024/12/11 2024.
https://www.pmda.go.jp/drugs/2024/P20241220002/780069000_30600AMX00298_A100_1.pdf.
67.
Chang LJ, Meng Y, Janosczyk H, Landolfi V, Talbot HK. Safety and immunogenicity of high-
dose quadrivalent influenza vaccine in adults ≥6 years of age: A phase 3 randomized clinical trial. Vaccine
2019; 37(39): 5825-34.
68.
Pepin S, Nicolas JF, Szymanski H, et al. Immunogenicity and safety of a quadrivalent high-dose
inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy
people aged 60 years or older: a randomized Phase III trial. Hum Vaccin Immunother 2021; 17(12): 547586.
69.
Sanchez L, Matsuoka O, Inoue S, et al. Immunogenicity and safety of high-dose quadrivalent
influenza vaccine in Japanese adults ≥65 years of age: a randomized controlled clinical trial. Hum Vaccin
Immunother 2020; 16(4): 858-66.
70.
Wilkinson K, Wei Y, Szwajcer A, et al. Efficacy and safety of high-dose influenza vaccine in
elderly adults: A systematic review and meta-analysis. Vaccine 2017; 35(21): 2775-80.
71.
Moro PL, Woo EJ, Marquez P, Cano M. Monitoring the safety of high-dose, trivalent inactivated
influenza vaccine in the vaccine adverse event reporting system (VAERS), 2011 - 2019. Vaccine 2020;
38(37): 5923-6.
72.
Palmu AA, Pepin S, Syrjänen RK, et al. High-Dose Quadrivalent Influenza Vaccine for
Prevention of Cardiovascular and Respiratory Hospitalizations in Older Adults. Influenza Other Respir
Viruses 2024; 18(4): e13270.
73.
Arya DP, Said MA, Izurieta HS, et al. Surveillance for Guillain-Barré syndrome after 2015-2016
40
61.
Lu Y, Chillarige Y, Izurieta HS, et al. Effect of Age on Relative Effectiveness of High-Dose
Versus Standard-Dose Influenza Vaccines Among US Medicare Beneficiaries Aged ≥65 Years. J Infect Dis
2019; 220(9): 1511-20.
62.
DiazGranados CA, Dunning AJ, Robertson CA, Talbot HK, Landolfi V, Greenberg DP. Effect of
Previous-Year Vaccination on the Efficacy, Immunogenicity, and Safety of High-Dose Inactivated
Influenza Vaccine in Older Adults. Clin Infect Dis 2016; 62(9): 1092-9.
63.
Christensen J, Johansen ND, Modin D, et al. Relative Effectiveness of High-Dose Versus
Standard-Dose Quadrivalent Influenza Vaccine in Older Adults With Cardiovascular Disease: A
Prespecified Analysis of the DANFLU-1 Randomized Clinical Trial. Circ Cardiovasc Qual Outcomes
2025; 18(2): e011496.
64.
Chaves SS, Naeger S, Lounaci K, et al. High-Dose Influenza Vaccine Is Associated With
Reduced Mortality Among Older Adults With Breakthrough Influenza Even When There Is Poor VaccineStrain Match. Clin Infect Dis 2023; 77(7): 1032-42.
65.
DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-dose
influenza vaccine in older adults. N Engl J Med 2014; 371(7): 635-45.
66.
独立行政法人医薬品医療機器総合機構. 審査報告書
高用量インフルエンザ HA ワクチン.
2024/12/11 2024.
https://www.pmda.go.jp/drugs/2024/P20241220002/780069000_30600AMX00298_A100_1.pdf.
67.
Chang LJ, Meng Y, Janosczyk H, Landolfi V, Talbot HK. Safety and immunogenicity of high-
dose quadrivalent influenza vaccine in adults ≥6 years of age: A phase 3 randomized clinical trial. Vaccine
2019; 37(39): 5825-34.
68.
Pepin S, Nicolas JF, Szymanski H, et al. Immunogenicity and safety of a quadrivalent high-dose
inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy
people aged 60 years or older: a randomized Phase III trial. Hum Vaccin Immunother 2021; 17(12): 547586.
69.
Sanchez L, Matsuoka O, Inoue S, et al. Immunogenicity and safety of high-dose quadrivalent
influenza vaccine in Japanese adults ≥65 years of age: a randomized controlled clinical trial. Hum Vaccin
Immunother 2020; 16(4): 858-66.
70.
Wilkinson K, Wei Y, Szwajcer A, et al. Efficacy and safety of high-dose influenza vaccine in
elderly adults: A systematic review and meta-analysis. Vaccine 2017; 35(21): 2775-80.
71.
Moro PL, Woo EJ, Marquez P, Cano M. Monitoring the safety of high-dose, trivalent inactivated
influenza vaccine in the vaccine adverse event reporting system (VAERS), 2011 - 2019. Vaccine 2020;
38(37): 5923-6.
72.
Palmu AA, Pepin S, Syrjänen RK, et al. High-Dose Quadrivalent Influenza Vaccine for
Prevention of Cardiovascular and Respiratory Hospitalizations in Older Adults. Influenza Other Respir
Viruses 2024; 18(4): e13270.
73.
Arya DP, Said MA, Izurieta HS, et al. Surveillance for Guillain-Barré syndrome after 2015-2016
40